Evidence map›Paper›PMID 27467585›Full record

ArticlePloS one2016

MRI as a Novel In Vivo Approach for Assessing Structural Changes of Chlamydia Pathology in a Mouse Model.

Catherine D G Hines, Shubing Wang, Xiangjun Meng, Julie M Skinner, Jon H Heinrichs, Jeffrey G Smith, Melissa A Boddicker

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Update on Chlamydia trachomatis Vaccinology.Clinical and vaccine immunology : CVI · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catherine D G HinesDepartment of Translational Imaging Biomarkers, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.ORCID http://orcid.org/0000-0001-9826-3164
Shubing WangDepartment of Biometrics Research, MRL (Rahway, NJ), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.
Xiangjun MengDepartment of Translational Imaging Biomarkers, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.
Julie M SkinnerDepartment of Vaccines Early Discovery, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.
Jon H HeinrichsGlobal Project Leadership, Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.
Jeffrey G SmithPharmaceutical Sciences Analytical Research & Development, Pfizer, Andover, Massachusetts, United States of America.
Melissa A BoddickerDepartment of Vaccines Early Discovery, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chlamydia trachomatis is among the most prevalent of sexually transmitted diseases. While Chlamydia infection is a reportable event and screening has increased over time, enhanced surveillance has not resulted in a reduction in the rate of infections, and Chlamydia infections frequently recur. The development of a preventative vaccine for Chlamydia may be the only effective approach for reducing infection and the frequency of pathological outcomes. Current vaccine research efforts involve time consuming and/or invasive approaches for assessment of disease state, and MRI presents a clinically translatable method for assessing infection and related pathology both quickly and non-invasively. Longitudinal T2-weighted MRI was performed over 63 days on both control or Chlamydia muridarum challenged mice, either with or without elementary body (EB) immunization, and gross necropsy was performed on day 65. A scoring system was developed to assess the number of regions affected by Chlamydia pathology and was used to document pathology over time and at necropsy. The scoring system documented increasing incidence of pathology in the unimmunized and challenged mice (significantly greater compared to the control and EB immunized-challenged groups) by 21 days post-challenge. No differences between the unchallenged and EB immunized-challenged mice were observed. MRI scores at Day 63 were consistently higher than gross necropsy scores at Day 65, although two of the three groups of mice showed no significant differences between the two techniques. In this work we describe the application of MRI in mice for the potential evaluation of disease pathology and sequelae caused by C. muridarum infection and this technique's potential for evaluation of vaccines for Chlamydia.

Indexed as

Disease Models, AnimalAnimalsChlamydia InfectionsHeLa CellsHumansMagnetic Resonance ImagingMice

Identifiers

PMID27467585
PMCPMC4965011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.